Integra Lifesciences Holdings (IART) Tops Q2 EPS by 5c; Boosts FY12 Sales Outlook

Integra Lifesciences Holdings (NASDAQ: IART) reported Q2 EPS of $0.74, $0.05 better than the analyst estimate of $0.69. Revenue for the quarter came in at $210.2 million versus the consensus estimate of $205.41 million.

Sees FY2012 revenue of $828-$838 million, versus the consensus of $829.62 million.

For earnings history and earnings-related data on Integra Lifesciences Holdings (IART) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Bank of America (BAC) Tops Q1 EPS by $0.07, Beats on Revenue
• Mitek Systems (MITK) Misses Q2 EPS by 4c, Offers Guidance
• Morgan Stanley (MS) earnings beat lifts stock